A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity

European Journal of Neurology

Volumn 18, Issue 9, 2011, Pages 1159-1164

  Depondt, C ^a   Godard, P ^b   Espel, R S ^b   da Cruz, A L ^a   Lienard, P ^b   Pandolfo, M ^a  

^a ERASME HOSPITAL   (Belgium)

^b DNAVision SA   (Belgium)

Author keywords

Antiepileptic drugs; Association; CYP2C9; Epilepsy; GSTM1; Pharmacogenetics

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 2C9; PHENYTOIN; VALPROIC ACID;

ADULT; AGITATION; AGRANULOCYTOSIS; ALLELE; ARTICLE; BLURRED VISION; BRAIN DISEASE; CONFUSION; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EPILEPSY; ERECTILE DYSFUNCTION; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GINGIVITIS; HAIR LOSS; HEADACHE; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; PANCREATITIS; PARKINSONISM; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RASH; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREMOR; VERTIGO; WEIGHT GAIN;

ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; EPILEPSY; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80051591108     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03361.x     Document Type: Article

References (25)

1. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008; 358: 637-639.
2. Woelderink A, Ibarreta D, Hopkins MM, Rodriguez-Cerezo E. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J 2006; 6: 3-7.
3. Tan NC, Berkovic SF. The Epilepsy Genetic Association Database (epiGAD): analysis of 165 genetic association studies, 1996-2008. Epilepsia 2010; 51: 686-689.
4. Kasperaviciute D, Sisodiya SM. Epilepsy pharmacogenetics. Pharmacogenomics 2009; 10: 817-836.
5. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9: 1543-1546.
6. Depondt C, Shorvon SD. Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications. Pharmacogenomics 2006; 7: 731-745.
7. HapMap Data Release 22 PI, April 2007, dbSNP126. Available at:.
8. Gonzalez JR, Armengol L, Sole X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644-645.
9. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 2009; 50: 898-903.
10. Cascorbi I. ABC transporters in drug-refractory epilepsy: limited clinical significance of pharmacogenetics? Clin Pharmacol Ther 2010; 87: 15-18.
11. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62: 382-389.
12. Del Felice A, Beghi E, Boero G, et al. Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia 2010; 51: 37-42.
13. Sillanpaa M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006; 129: 617-624.
14. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26: 753-759.
15. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*. Clin Pharmacol Ther 2001; 70: 391-394.
16. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000; 22: 230-232.
17. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005; 102: 5507-5512.
18. Bu HZ, Kang P, Deese AJ, Zhao P, Pool WF. Human in vitro glutathionyl and protein adducts of carbamazepine-10, 11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab Dispos 2005; 33: 1920-1924.
19. Madden S, Maggs JL, Park BK. Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab Dispos 1996; 24: 469-479.
20. Board P, Coggan M, Johnston P, Ross V, Suzuki T, Webb G. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol Ther 1990; 48: 357-369.
21. Fukushima Y, Seo T, Hashimoto N, Higa Y, Ishitsu T, Nakagawa K. Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum gamma-glutamyltransferase in valproic acid-treated patients. Clin Chim Acta 2008; 389: 98-102.
22. Ueda K, Ishitsu T, Seo T, et al. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics 2007; 8: 435-442.
23. Ioannidis JP. Genetic associations: false or true? Trends Mol Med 2003; 9: 135-138.
24. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33: 177-182.
25. Petrovski S, Szoeke CE, Sheffield LJ, D'Souza W, Huggins RM, O'Brien TJ. Multi-SNP pharmacogenomic classifier is superior to single-SNP models for predicting drug outcome in complex diseases. Pharmacogenet Genomics 2009; 19: 147-152.